NEW YORK and RED BANK, N.J., Dec. 8,
2020 /PRNewswire/ -- On the heels of National Diabetes
Awareness Month, JDRF, the leading global funder of type 1 diabetes
(T1D) research, has launched a groundbreaking screening initiative
for T1D: T1Detect. Designed to make early detection of T1D
easier and more accessible to a broad population, financial
assistance is available for the cost of the screening. The
initiative is supported by founding sponsor Provention Bio (Nasdaq:
PRVB), a biopharmaceutical company focused on intercepting and
preventing autoimmune disease.
Detecting T1D before symptoms occur is possible through a blood
test when people have two or more diabetes-related autoantibodies
and blood sugar levels have become abnormal. Research has proven
that 75 percent of people at this stage will become
insulin-dependent within five years. Their lifetime risk of
clinical disease approaches 100 percent.i
Approximately 85 percentii of people with T1D have no
family history, underscoring the necessity for an all-population
screening. T1Detect will be available to people of all ages
whether or not they have a family member with T1D.
"T1Detect is the first and only screening program that
will enable a broad population to know their risk of T1D," said
Aaron J. Kowalski, Ph.D., President
and CEO of JDRF. "This groundbreaking initiative is an important
milestone for JDRF because it will increase awareness about
early-stage T1D, provide access to crucial education and support
for those at risk, and pave the way to ensuring that T1D screening
becomes part of universal, clinical preventive services."
JDRF-funded screening consortia and studies, such as TrialNet,
INNODIA, FR1da, and ASK, have shown that identifying at-risk
individuals, along with education and monitoring for those found to
be positive, reduces the risk of diabetic ketoacidosis, which can
be life-threatening, and expands the pool of qualified
participants for future trials of disease-modifying therapies.
Early detection also enables patients and families to prepare for
the onset of clinical disease and a lifetime of insulin
administration and glucose monitoring.
"Provention Bio is proud to support JDRF's screening
initiative," said Ashleigh Palmer,
CEO of Provention Bio. "We are committed to working with partners
in the T1D community to find new ways to empower patients and
doctors with information that could lead to more informed
healthcare decisions."
JDRF has brought together a multi-sectoral collaboration to
expand access to T1D screening, including MedIQ, which will provide
clinician education, Nuvera Life Science Consulting, which will
advise on program design and operations and Enable Biosciences,
which will conduct the screenings. Under the JDRF-Beyond Type 1
Alliance, Beyond Type 1 will support community education and
awareness. The multi-year initiative is supported by both
individual gifts and corporate sponsors.
For more information about the T1Detect initiative
and how to obtain an at-home testing kit visit,
www.jdrf.org/t1detect. Test kits are only available for shipping
within the United States and
Puerto Rico.
About JDRF
JDRF's mission is to accelerate life-changing breakthroughs to
cure, prevent, and treat T1D and its complications. To accomplish
this, JDRF has invested more than $2.5
billion in research funding since our inception. We are an
organization built on a grassroots model of people connecting in
their local communities, collaborating regionally for efficiency
and broader fundraising impact and uniting on a national stage to
pool resources, passion and energy. We collaborate with academic
institutions, policymakers and corporate and industry partners to
develop and deliver a pipeline of innovative therapies to people
living with T1D. Our staff and volunteers throughout the United States and our five international
affiliates are dedicated to advocacy, community engagement and our
vision of a world without T1D. For more information, please visit
jdrf.org or follow us on Twitter: @JDRF
About Provention Bio, Inc.:
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical
company focused on advancing the development of investigational
therapies that may intercept and prevent debilitating and
life-threatening immune-mediated disease. The Company's pipeline
includes clinical product development candidates that have
demonstrated in clinical studies proof-of-mechanism and/or
proof-of-concept in autoimmune diseases, including diabetes,
celiac disease and lupus. Visit ProventionBio.com for more
information or follow us on Twitter: @ProventionBio
i https://care.diabetesjournals.org/content/38/10/1964
ii https://www.ncbi.nlm.nih.gov/books/NBK326738/
View original content to download
multimedia:http://www.prnewswire.com/news-releases/jdrf-launches-first-mass-screening-program-for-early-stage-type-1-diabetes-t1d-detection-301187886.html
SOURCE JDRF